

17. Okita K, Yamanaka S (2011) Induced pluripotent stem cells: opportunities and challenges. *Philos Trans R Soc Lond B Biol Sci* 366: 2198–2207.
18. Stadtfeld M, Maherali N, Breault DT, Hochedlinger K (2008) Defining molecular cornerstones during fibroblast to iPSC cell reprogramming in mouse. *Cell Stem Cell* 2: 230–240.
19. Cheung HH, Liu X, Canterel-Thouennon L, Li L, Edmonson C, et al. (2014) Telomerase protects werner syndrome lineage-specific stem cells from premature aging. *Stem Cell Reports* 2: 534–546.
20. Batista LF, Pech MF, Zhong FL, Nguyen HN, Xie KT, et al. (2011) Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. *Nature* 474: 399–402.
21. Goto M, Ishikawa Y, Sugimoto M, Furuichi Y (2013) Werner syndrome: A changing pattern of clinical manifestations in Japan (1917–2008). *Biosci Trends* 7: 13–22.
22. Morita S, Kojima T, Kitamura T (2000) Plat-E: an efficient and stable system for transient packaging of retroviruses. *Gene Ther* 7: 1063–1066.
23. Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, et al. (2011) Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. *Nat Biotechnol* 29: 1132–1144.
24. Ohtaki K, Spoto R, Kodama Y, Nakano M, Awa AA (1994) Aneuploidy in somatic cells of in utero exposed A-bomb survivors in Hiroshima. *Mutat Res* 316: 49–58.
25. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O (2009) Protocols to detect senescence-associated beta-galactosidase (SA-beta-gal) activity, a biomarker of senescent cells in culture and in vivo. *Nat Protoc* 4: 1798–1806.
26. Goto M (2008) Inflammaging (inflammation + aging): A driving force for human aging based on an evolutionarily antagonistic pleiotropy theory? *Biosci Trends* 2: 218–230.
27. Salama R, Sadaie M, Hoare M, Narita M (2014) Cellular senescence and its effector programs. *Genes Dev* 28: 99–114.
28. Kojima H, Kunimoto H, Inoue T, Nakajima K (2012) The STAT3-IGFBP5 axis is critical for IL-6/gp130-induced premature senescence in human fibroblasts. *Cell Cycle* 11:
29. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR (2008) Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. *Cell* 132: 363–374.
30. Tabata M, Kadomatsu T, Fukuhara S, Miyata K, Ito Y, et al. (2009) Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. *Cell Metab* 10: 178–188.
31. Gilbert LA, Hemann MT (2010) DNA damage-mediated induction of a chemo-resistant niche. *Cell* 143: 355–366.
32. Wyllie FS, Jones CJ, Skinner JW, Houghton MF, Wallis C, et al. (2000) Telomerase prevents the accelerated cell ageing of Werner syndrome fibroblasts. *Nat Genet* 24: 16–17.
33. Salk D, Au K, Hoehn H, Stenchever MR, Martin GM (1981) Evidence of clonal attenuation, clonal succession, and clonal expansion in mass cultures of aging Werner's syndrome skin fibroblasts. *Cytogenet Cell Genet* 30: 108–117.
34. Mathew R, Jia W, Sharma A, Zhao Y, Clarke LE, et al. (2010) Robust activation of the human but not mouse telomerase gene during the induction of pluripotency. *FASEB J* 24: 2702–2715.
35. Vaziri H, Chapman K, Guigova A, Teichroeb J, Lacher M, et al. (2010) Spontaneous reversal of the developmental aging of normal human cells following transcriptional reprogramming. *Regen Med* 5: 345–363.
36. Taapken SM, Nisler BS, Newton MA, Sampsell-Barron TL, Leonhard KA, et al. (2011) Karyotypic abnormalities in human induced pluripotent stem cells and embryonic stem cells. *Nat Biotechnol* 29: 313–314.
37. Martins-Taylor K, Nisler BS, Taapken SM, Compton T, Crandall L, et al. (2011) Recurrent copy number variations in human induced pluripotent stem cells. *Nat Biotechnol* 29: 488–491.
38. Kumar S, Vinci JM, Millis AJ, Baglioni C (1993) Expression of interleukin-1 alpha and beta in early passage fibroblasts from aging individuals. *Exp Gerontol* 28: 505–513.
39. Murano S, Nakazawa A, Saito I, Masuda M, Morisaki N, et al. (1997) Increased blood plasminogen activator inhibitor-1 and intercellular adhesion molecule-1 as possible risk factors of atherosclerosis in Werner syndrome. *Gerontology* 43 Suppl 1: 43–52.
40. Yokote K, Hara K, Mori S, Kadowaki T, Saito Y, et al. (2004) Dysadipocytokinaemia in werner syndrome and its recovery by treatment with pioglitazone. *Diabetes Care* 27: 2562–2563.
41. Rubin CD, Zerwekh JE, Reed-Gitomer BY, Pak CY (1992) Characterization of osteoporosis in a patient with Werner's syndrome. *J Am Geriatr Soc* 40: 1161–1163.
42. Davis T, Kipling D (2006) Werner Syndrome as an example of inflamm-aging: possible therapeutic opportunities for a progeroid syndrome? *Rejuvenation Res* 9: 402–407.
43. Goto M, Sugimoto K, Hayashi S, Ogino T, Sugimoto M, et al. (2012) Aging-associated inflammation in healthy Japanese individuals and patients with Werner syndrome. *Exp Gerontol* 47: 936–939.
44. Choi D, Whittier PS, Oshima J, Funk WD (2001) Telomerase expression prevents replicative senescence but does not fully reset mRNA expression patterns in Werner syndrome cell strains. *FASEB J* 15: 1014–1020.

